Home>Topics>Stocks>GlaxoSmithKline PLC ADR

GlaxoSmithKline PLC ADR GSK

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. Arzerra gets label expansion

      Headlines

      Thu, 17 Apr 2014

      The FDA approves Glaxo ( GSK ) and Genmab's ( OTC:GNMSF ) monoclonal antibody Arzerra (ofatumumab) as a first-line therapy for patients with chronic

    2. Ellipta cleared in Canada

      Headlines

      Thu, 17 Apr 2014

      Glaxo's ( GSK -0.5% ) once-daily long-term bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary

    3. BRIEF- GSK gets Canadian approval for bronchodilator treatment Incruse

      Headlines

      Thu, 17 Apr 2014

      * Glaxosmithkline plc gsk receives approval in Canada for incruse

    4. GSK , facing bribery claims, battles to build new sales model

      Headlines

      Thu, 17 Apr 2014

      LONDON (Reuters) - Drugmaker GlaxoSmithKline - hit by bribery claims in five countries - is to employ hundreds more doctors as members of staff as it seeks to build a new sales model designed to eliminate sharp marketing practices.

    5. GSK , facing bribery claims, battles to build new sales model

      Headlines

      Thu, 17 Apr 2014

      * GSK hopes for long-term competitive advantage with revamp

    6. Galapagos, GSK successfully conclude phase 2a study of skin disease drug

      Headlines

      Thu, 17 Apr 2014

      BRUSSELS, April 17 (Reuters) - Belgian biotech group Galapagos NV on Thursday said it has successfully concluded the phase 2a study of a skin disease drug it is developing with Britain's GlaxoSmithKline PLC.

    7. GSK adds two more countries to its list

      Headlines

      Wed, 16 Apr 2014

      GlaxoSmitKline ( GSK +0.9% ) investigates its sales operations in Lebanon and Jordan over alleged free samples and travel benefits to doctors in

    8. UPDATE 1- GSK says investigating claims of bribery in Jordan, Lebanon

      Headlines

      Wed, 16 Apr 2014

      * Follows earlier claims of bribes in China, Poland, Iraq (Adds details on allegations, further GSK comment)

    9. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Wed, 16 Apr 2014

      relatively empty drug pipelines in part by buying up biotech firms. That has culminated in deals such as GlaxoSmithKline's GSK acquisition in 2012 of Human Genome Sciences. Given Big Pharma's flush balance sheets, we expect more biotechs to be acquired

    10. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Wed, 16 Apr 2014

      relatively empty drug pipelines in part by buying up biotech firms. That has culminated in deals such as GlaxoSmithKline's GSK acquisition in 2012 of Human Genome Sciences. Given Big Pharma's flush balance sheets, we expect more biotechs to be acquired

    « Prev12345Next »
    Content Partners